Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.13USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.13
Open
$1.15
Day's High
$1.15
Day's Low
$1.12
Volume
40,284
Avg. Vol
73,462
52-wk High
$1.42
52-wk Low
$0.80

BLRX.OQ

Chart for BLRX.OQ

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -- -- --
ROI: -- 2.87 14.88
ROE: -- 5.20 16.12

BRIEF-Biolinerx Q2 ‍loss per share $0.05​

* Qtrly ‍loss per share $0.05​ Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

Jul 26 2017

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

Jul 26 2017

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

Jun 01 2017

BRIEF-BioLine Rx reports Q1 loss per share $0.06

* BioLine Rx Ltd qtrly loss per share $0.06 Source text for Eikon: Further company coverage:

May 25 2017

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

May 22 2017

BRIEF-BioLineRx to begin late-stage study testing stem cell treatment

* Biolinerx to initiate phase 3 study with bl-8040 as novel stem cell mobilization treatment following successful meeting with fda

May 03 2017

BRIEF-BVF Inc reports 18.3 pct passive stake in Bioline RX Ltd

* BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017 Source text:(http://bit.ly/2p0kRot) Further company coverage:

Apr 10 2017

BRIEF-BioLineRx prices $25 mln underwritten public offering

* BioLine rx ltd - priced underwritten public offering of about 29.4 million ADSs at public offering price of $0.85 per ads Source text for Eikon: Further company coverage:

Mar 31 2017

BRIEF-BioLine RX announces underwritten public offering of its american depositary shares

* BioLine RX announces underwritten public offering of its american depositary shares

Mar 30 2017

Earnings vs. Estimates